Improving Access to Clinical Trials: American Kidney Fund Adds User-Friendly Search Capability and Information to KidneyFund.org
FOR IMMEDIATE RELEASE
‘Antidote Match™’ technology makes it easy to find suitable trials in seconds
ROCKVILLE, Maryland (Nov. 10, 2016)—It’s about to become a lot easier for kidney patients to find information on clinical trials that may be suitable to them. The American Kidney Fund (AKF) today announced it is partnering with Antidote, an innovative digital health company, to incorporate the company’s “Antidote Match” clinical trial search tool on KidneyFund.org.
Antidote Match is an online platform that aggregates all publicly available information on clinical trials and presents them in plain language and an easily searchable format. Patients answer a series of questions online about their kidney disease and medical history and then receive a customized list of available trials in their region to review with their health care providers. Patients do not need to provide any personal identifying information when searching for information on clinical trials.
“For many patients, clinical trials can offer hope when current treatments are not producing the best results,” said LaVarne A. Burton, president and CEO of the American Kidney Fund. “Until now, the sources of clinical trial information were complicated, difficult to use, and often produced search results that were not relevant. We are pleased to integrate Antidote’s technology into KidneyFund.org to make it easy for patients to learn more about innovative clinical trials for kidney disease and related conditions.”
“I was diagnosed with stage IV kidney cancer, and a clinical trial saved my life,” said Dave deBronkart, patient perspectives advisor for Antidote. “But most patients are not aware that a trial may even be an option for them. Antidote’s collaboration with the American Kidney Fund will help make sure that patients get the right information about clinical trials at the point of need.”
Antidote Match was developed to bridge the gap between patients and researchers who are developing new medical treatments for diseases. The search tool can be found at www.kidneyfund.org/clinical-trials. AKF is also planning a webinar for early 2017 that will educate patients and their families about clinical trials—what they are, how they are run and what to expect.
About the American Kidney Fund
As the nation’s leading nonprofit working on behalf of the 31 million Americans with kidney disease, the American Kidney Fund is dedicated to ensuring that every kidney patient has access to health care, and that every person at risk for kidney disease is empowered to prevent it. AKF provides a complete spectrum of programs and services: prevention outreach, top-rated health educational resources, and direct financial assistance enabling 1 in 5 U.S. dialysis patients to access lifesaving medical care, including dialysis and transplantation.
Antidote is a digital health company on a mission. Their aim is to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need them. In a world where 80% of clinical trials are delayed or closed due to lack of awareness, Antidote uses cutting-edge technology to match the right patients with the right trials, helping medical researchers make faster progress, and offering new treatment options to patients in need. Antidote was launched as TrialReach in 2010, and is based in the US and UK. This is a global effort to advance health care for everyone. To find out how you can help shape medical history, visit http://www.antidote.me.
# # #